Floating Button
Home Views Healthcare

Will the new IP changes help with medical inflation?

Felicia Tan
Felicia Tan • 4 min read
Will the new IP changes help with medical inflation?
Singapore curbs overuse, but not the real drivers of rising healthcare costs. Photo: Bloomberg
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Growing up, I’d often hear my grandmother say it’s better to die than to fall ill in Singapore. With the country’s medical cost inflation — having stayed below 10% in 2024, had shot up again and is seen to hit a new high of 16.9% in 2026, up from 2025 — she may be right.

On Nov 26, 2025, the Ministry of Health (MOH) announced new requirements for integrated shield plan (IP) riders. From April 1, insurers can no longer sell riders that cover the minimum IP deductible, and the co-payment cap will also be doubled to a minimum of $6,000, excluding the minimum deductible. This means Singaporeans will have to pay more for smaller bills, but new riders are expected to be priced around 30% lower. All seven IP insurers have launched compliant products on April 1, with the new riders 16% to 84% cheaper than previous versions.

The changes, according to MOH, will help bring health insurance back to its original objective to protect against larger healthcare bills. The ministry’s data shows private hospital IP policyholders with riders are 1.4 times as likely to make a claim, with an average claim size of 1.4 times that of those without riders.

Health Minister Ong Ye Kung described the overly-generous coverage in private insurance as a “classic buffet syndrome”, which drove up claims and insurance premiums. “Yet it is frustrating to see insurance companies continue to offer unsustainable terms, presumably competing for market share,” he said in 2024.

The new structure bets that skin in the game will change the behaviour on both sides. A $3,500 deductible for private hospital admissions will have patients thinking twice before opting for that private hospital stay. At the same time, doctors may think twice about recommending more expensive and additional treatments when a simpler one will do.

Structural shifts

See also: Merck to acquire Terns Pharmaceuticals in US$6.7 bil deal

In theory, less overconsumption leads to smaller claims and lower premiums. However, the rider changes will still not address structural shifts. WTW’s research cited new medical technologies to be the top reason for increased costs, followed by advancements in pharmaceuticals and the little or the lack of cost sharing.

The rising number of cancer diagnoses illustrates the scale of the challenge. The latest Singapore Cancer Registry annual report also showed an increase in cancer diagnoses for those under 40. Between 2019 and 2023, there were 4,995 diagnoses, 34% higher than the 3,729 reported between 2003 and 2007.

The earliest period on record in the report, which is between 1968 and 1972, showed the number of cancer diagnoses for the same age group at 1,710, as highlighted by The Straits Times. The Singapore Cancer Society estimates that one in four Singapore residents is at risk of getting cancer by the age of 75.

See also: TPG sets up regional aged care platform consolidating operators in Singapore, Malaysia

Straightforward win

In that sense, higher co-payments may not help make targeted therapies cheaper or slow tumour growth. So, who do the changes actually help?

In the near term, younger and healthier policyholders stand to benefit most, with lower premiums being a straightforward win. MOH’s own illustration shows a 40-year-old who previously couldn’t afford a rider can now add one under the new pricing.

Older policyholders, who are more likely actually to use their insurance, may find the calculation less straightforward. While they get to save on premiums, the higher out-of-pocket exposure per hospitalisation may offset that.

Again, using MOH’s example, a 60-year-old undergoing knee replacement surgery under the new structure would pay $3,330 more from his MediSave per episode than under the old rider, even after accounting for premium savings over three years.

Insurers are not certain if lower premiums can move the needle towards more sustainable healthcare. Consumers, on their part, are not fully aware of what the changes entail. All parties involved have more work cut out for themselves.

Ultimately, my grandmother’s instinct wasn’t wrong — getting sick in Singapore is expensive, and it’s getting more so. The IP rider changes are a meaningful intervention, but they’re fighting behavioural inflation in a system where most of the inflation is structural. Fixing the buffet syndrome is a start. Whether it is enough will only be answered with time.

×
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2026 The Edge Publishing Pte Ltd. All rights reserved.